CAJ | 학술논문

目的：评价尼麦角林联合奥拉西坦治疗血管性认知功能障碍（ VCI ）的临床疗效及安全性。方法入选本科门诊及住院诊治的VCI患者122例，随机分为尼麦角林组38例，给予尼麦角林10 mg，tid；奥拉西坦组41例，给予奥拉西坦800 mg，tid；联合用药组43例，同时服用上述2种药物，剂量相同。3组患者共治疗3个月，比较治疗前后的认知功能评分（ MoCA）、生活能力评分（ ADL）及不良反应发生率。结果与治疗前比较，治疗3个月后，3组患者MoCA评分均显著升高（ P＜0.05），ADL评分均显著降低（ P＜0.05）；但联合用药组的上述指标变化更为显著，与其他2组比较差别有统计学意义（ P＜0.05）。3组患者服药期间均无明显不良反应。结论奥拉西坦联合尼麦角林治疗血管性认知功能障碍疗效好于单一用药，且不增加药物不良反应。
목적：평개니맥각림연합오랍서탄치료혈관성인지공능장애（ VCI ）적림상료효급안전성。방법입선본과문진급주원진치적VCI환자122례，수궤분위니맥각림조38례，급여니맥각림10 mg，tid；오랍서탄조41례，급여오랍서탄800 mg，tid；연합용약조43례，동시복용상술2충약물，제량상동。3조환자공치료3개월，비교치료전후적인지공능평분（ MoCA）、생활능력평분（ ADL）급불량반응발생솔。결과여치료전비교，치료3개월후，3조환자MoCA평분균현저승고（ P＜0.05），ADL평분균현저강저（ P＜0.05）；단연합용약조적상술지표변화경위현저，여기타2조비교차별유통계학의의（ P＜0.05）。3조환자복약기간균무명현불량반응。결론오랍서탄연합니맥각림치료혈관성인지공능장애료효호우단일용약，차불증가약물불량반응。
Objective To evaluate the clinical efficacy and safety of nicergoline combined with oxiracetam in the treatment of vascular cogni-tive impairment(VCI).Methods One hundred and twenty -two sub-jects with VCI were randomly divided into nicergoline group ( n =38 ) with nicergoline 10 mg, tid po, oxiracetam group ( n=41) with oxirace-tam 800 mg, tid po, and combined group(n=43)with nicergoline plus oxiracetam of the same dose.After three-month treatment , the Mon-treal Cognitive Assessment ( MoCA) and activities of daily living ( ADL) scale were compared before and after the treatment to evaluate the im-provement of cognitive and activities of daily living ability as well as the side effects of the two drugs.Results After 3-month treatment , MoCA score was significantly elevated ( P<0.05 ) and ADL was significantly reduced in all of the three groups ( P<0.05 ) , and the changes in the combined group was much more obvious than those of the other two groups ( P<0.05 ).No obvious side effects were observed in the periods of treatment in all the three groups.Conclusion Combined treatment was superior to either of the single regiment in the treatment of VCI with-out increasing the risk of developing side effects.